At the time of writing, Atyr Pharma Inc [ATYR] stock is trading at $0.84, up 1.42%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ATYR shares have gain 15.93% over the last week, with a monthly amount drifted -84.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atyr Pharma Inc [NASDAQ: ATYR] stock has seen the most recent analyst activity on September 16, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform but kept the price target unchanged to $1.50 for it. Previously, Wells Fargo downgraded its rating to Equal Weight on September 15, 2025, and kept the price target unchanged to $1. On September 15, 2025, downgrade downgraded it’s rating to Market Perform but maintained its price target of $1 on the stock. H.C. Wainwright downgraded its rating to a Neutral. Cantor Fitzgerald downgraded its rating to a Neutral. Leerink Partners started tracking with a Outperform rating for this stock on February 18, 2025, and assigned it a price target of $16. In a note dated January 06, 2025, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Atyr Pharma Inc fluctuated between $0.68 and $7.29. Currently, Wall Street analysts expect the stock to reach $5.13 within the next 12 months. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $0.84 at the most recent close of the market. An investor can expect a potential return of 510.71% based on the average ATYR price forecast.
Analyzing the ATYR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.93 and Total Capital is -0.81. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8082 points at the first support level, and at 0.7802 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8556, and for the 2nd resistance point, it is at 0.8750.
Ratios To Look Out For
It is important to note that Atyr Pharma Inc [NASDAQ:ATYR] has a current ratio of 5.63. As well, the Quick Ratio is 5.63, while the Cash Ratio is 1.11.
Transactions by insiders
Recent insider trading involved Gross Jane A, Director, that happened on Mar 17 ’25 when 3750.0 shares were purchased. Chief Financial Officer, Broadfoot Jill Marie completed a deal on Feb 04 ’25 to sell 1254.0 shares. Meanwhile, General Counsel DENYES NANCY sold 899.0 shares on Feb 04 ’25.
